Papillary thyroid cancer: monitoring and therapy.

[1]  N. Lee,et al.  The role of external beam radiotherapy in the treatment of papillary thyroid cancer. , 2006, Endocrine-related cancer.

[2]  H. Welch,et al.  Epidemiology of head and neck cancer in the United States , 2006, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[3]  W. Wiersinga,et al.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. , 2006, European journal of endocrinology.

[4]  Louise Davies,et al.  Increasing incidence of thyroid cancer in the United States, 1973-2002. , 2006, JAMA.

[5]  Gerard M Doherty,et al.  Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2006, Thyroid : official journal of the American Thyroid Association.

[6]  M. Stokkel,et al.  The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature. , 2006, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[7]  Mithat Gonen,et al.  Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. , 2006, The Journal of clinical endocrinology and metabolism.

[8]  J. Shah,et al.  Low-risk differentiated thyroid cancer: The need for selective treatment , 1997, Annals of Surgical Oncology.

[9]  E. Baudin,et al.  Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. , 2006, The Journal of clinical endocrinology and metabolism.

[10]  Anil T Ahuja,et al.  Ultrasound of thyroid cancer , 2005, Cancer imaging : the official publication of the International Cancer Imaging Society.

[11]  A. Schneider,et al.  Long-term risks for thyroid cancer and other neoplasms after exposure to radiation , 2005, Nature Clinical Practice Endocrinology &Metabolism.

[12]  B. Biondi,et al.  Thyroid-hormone therapy and thyroid cancer: a reassessment , 2005, Nature Clinical Practice Endocrinology &Metabolism.

[13]  C. Spencer,et al.  Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. , 2005, The Journal of clinical endocrinology and metabolism.

[14]  S. Larson,et al.  Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. , 2004, The Journal of clinical endocrinology and metabolism.

[15]  J. Watkinson,et al.  The British Thyroid Association guidelines for the management of thyroid cancer in adults , 2004, Nuclear medicine communications.

[16]  H. Gerstein,et al.  A Systematic Review and Metaanalysis of the Effectiveness of Radioactive Iodine Remnant Ablation for Well-Differentiated Thyroid Cancer , 2004 .

[17]  C. Spencer.  Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies. , 2004, The Journal of clinical endocrinology and metabolism.

[18]  Theresa M. Lee,et al.  Surgeon-Performed Ultrasound in the Management of Thyroid Malignancy , 2004, The American surgeon.

[19]  Sendia Kim,et al.  Predicting outcome and directing therapy for papillary thyroid carcinoma. , 2004, Archives of surgery.

[20]  Ho Kyu Lee,et al.  Ultrasonography‐guided fine‐needle aspiration of thyroid incidentaloma: correlation with pathological findings , 2004, Clinical endocrinology.

[21]  H. Hundeshagen,et al.  Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer , 1994, World Journal of Surgery.

[22]  A. Pinchera,et al.  Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.

[23]  J. Chan,et al.  Papillary microcarcinoma of the thyroid—Prognostic significance of lymph node metastasis and multifocality , 2003, Cancer.

[24]  Stephanie L. Lee,et al.  A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.

[25]  A. Miyauchi,et al.  An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. , 2003, Thyroid : official journal of the American Thyroid Association.

[26]  S. Nagataki,et al.  Epidemiology and primary prevention of thyroid cancer. , 2002, Thyroid : official journal of the American Thyroid Association.

[27]  A. Oberg,et al.  Papillary Thyroid Carcinoma Managed at the Mayo Clinic during Six Decades (1940–1999): Temporal Trends in Initial Therapy and Long-term Outcome in 2444 Consecutively Treated Patients , 2002, World Journal of Surgery.

[28]  S. Larson,et al.  Positron emission tomography in thyroid cancer management. , 2002, Seminars in roentgenology.

[29]  S. Takao,et al.  Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma. , 2002, Surgery.

[30]  G. Csako,et al.  Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer , 2002, Annals of medicine.

[31]  S. Larson,et al.  Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. , 2001, Thyroid : official journal of the American Thyroid Association.

[32]  A. Pinchera,et al.  Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. , 2001, The Journal of clinical endocrinology and metabolism.

[33]  R. Kloos,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society CLINICAL REVIEW 128 Current Approaches to Primary Therapy for Papillary , 2022 .

[34]  H. Gharib,et al.  AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. , 2001, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[35]  Spencer Ca.  Serum thyroglobulin measurements: clinical utility and technical limitations in the management of patients with differentiated thyroid carcinomas. , 2000 .

[36]  J. Shah,et al.  Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996 , 2000, Cancer.

[37]  D. Dean,et al.  Prognostic indicators in differentiated thyroid carcinoma. , 2000, Cancer control : journal of the Moffitt Cancer Center.

[38]  C. Malchoff,et al.  Familial nonmedullary thyroid carcinoma. , 2006, Seminars in surgical oncology.

[39]  I. Sugitani,et al.  Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors. , 1999, Endocrine journal.

[40]  E. Bergstralh,et al.  Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? , 1998, Surgery.

[41]  T. Ishigaki,et al.  Preoperative staging of thyroid papillary carcinoma with ultrasonography. , 1998, European journal of radiology.

[42]  P. Ladenson,et al.  Outcome after Treatment of High-Risk Papillary and Non-Hurthle-Cell Follicular Thyroid Carcinoma , 1998, Annals of Internal Medicine.

[43]  P. Ladenson,et al.  Prospective multicenter study of thyroid carcinoma treatment , 1998 .

[44]  P. Ladenson,et al.  Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. , 1998, Cancer.

[45]  B. Cady,et al.  Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. , 1998, Archives of surgery.

[46]  P. Ladenson,et al.  Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. , 1998, Thyroid : official journal of the American Thyroid Association.

[47]  B. O'Sullivan,et al.  A comparison of different staging systems predictability of patient outcome , 1997, Cancer.

[48]  S. Filetti,et al.  Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes. , 1997, The Journal of clinical endocrinology and metabolism.

[49]  E. Mazzaferri.  Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. , 1997, Thyroid : official journal of the American Thyroid Association.

[50]  C. Key,et al.  Prognostic factors for thyroid carcinoma , 1997, Cancer.

[51]  J. Bringer,et al.  Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. , 1996, The Journal of clinical endocrinology and metabolism.

[52]  I. Hay,et al.  Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. , 1996, Surgical oncology clinics of North America.

[53]  J. Shah,et al.  Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. , 1995, Surgery.

[54]  S. Jhiang,et al.  Differentiated thyroid cancer long-term impact of initial therapy. , 1995, Transactions of the American Clinical and Climatological Association.

[55]  S. Jhiang,et al.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. , 1994, The American journal of medicine.

[56]  P. Ladenson,et al.  Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. , 1994, The Journal of clinical endocrinology and metabolism.

[57]  E. Bergstralh,et al.  Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. , 1993, Surgery.

[58]  D. Johnston,et al.  The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. , 1992, The Journal of clinical endocrinology and metabolism.

[59]  I. Hay.  Papillary thyroid carcinoma. , 1990, Endocrinology and metabolism clinics of North America.

[60]  E. Kaplan,et al.  Natural history, treatment, and course of papillary thyroid carcinoma. , 1990, The Journal of clinical endocrinology and metabolism.

[61]  B. Cady,et al.  An expanded view of risk-group definition in differentiated thyroid carcinoma. , 1988, Surgery.

[62]  W. Taylor,et al.  Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. , 1987, Surgery.

[63]  L. Woolner,et al.  Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. , 1986, Mayo Clinic proceedings.

[64]  M. van Glabbeke,et al.  A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. , 1979, European journal of cancer.